192 related articles for article (PubMed ID: 23380816)
1. Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.
Schmiedel BJ; Werner A; Steinbacher J; Nuebling T; Buechele C; Grosse-Hovest L; Salih HR
Mol Ther; 2013 Apr; 21(4):877-86. PubMed ID: 23380816
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
Buechele C; Baessler T; Wirths S; Schmohl JU; Schmiedel BJ; Salih HR
Leukemia; 2012 May; 26(5):991-1000. PubMed ID: 22064350
[TBL] [Abstract][Full Text] [Related]
3. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
4. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.
Baessler T; Krusch M; Schmiedel BJ; Kloss M; Baltz KM; Wacker A; Schmetzer HM; Salih HR
Cancer Res; 2009 Feb; 69(3):1037-45. PubMed ID: 19155305
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions.
Baltz KM; Krusch M; Bringmann A; Brossart P; Mayer F; Kloss M; Baessler T; Kumbier I; Peterfi A; Kupka S; Kroeber S; Menzel D; Radsak MP; Rammensee HG; Salih HR
FASEB J; 2007 Aug; 21(10):2442-54. PubMed ID: 17360848
[TBL] [Abstract][Full Text] [Related]
7. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
8. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.
Schmiedel BJ; Scheible CA; Nuebling T; Kopp HG; Wirths S; Azuma M; Schneider P; Jung G; Grosse-Hovest L; Salih HR
Cancer Res; 2013 Jan; 73(2):683-94. PubMed ID: 23139212
[TBL] [Abstract][Full Text] [Related]
9. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia.
Koerner SP; André MC; Leibold JS; Kousis PC; Kübler A; Pal M; Haen SP; Bühring HJ; Grosse-Hovest L; Jung G; Salih HR
Leukemia; 2017 Feb; 31(2):459-469. PubMed ID: 27435001
[TBL] [Abstract][Full Text] [Related]
10. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
11. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
[TBL] [Abstract][Full Text] [Related]
14. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
15. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion.
Lacal PM; Petrillo MG; Ruffini F; Muzi A; Bianchini R; Ronchetti S; Migliorati G; Riccardi C; Graziani G; Nocentini G
J Pharmacol Exp Ther; 2013 Oct; 347(1):164-72. PubMed ID: 23892569
[TBL] [Abstract][Full Text] [Related]
17. Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody.
Schmied BJ; Lutz MS; Riegg F; Zekri L; Heitmann JS; Bühring HJ; Jung G; Salih HR
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817795
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis.
Liu B; Li Z; Mahesh SP; Pantanelli S; Hwang FS; Siu WO; Nussenblatt RB
J Biol Chem; 2008 Mar; 283(13):8202-10. PubMed ID: 18230609
[TBL] [Abstract][Full Text] [Related]
19. GITR controls intestinal inflammation by suppressing IL-15-dependent NK cell activity.
Sakurai T; Okuyama Y; Kobayashi S; Phung HT; Asao A; Kawabe T; Ndhlovu LC; Riccardi C; Kudo H; Wada M; Nio M; So T; Ishii N
FASEB J; 2020 Nov; 34(11):14820-14831. PubMed ID: 32910505
[TBL] [Abstract][Full Text] [Related]
20. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
